Adaptimmune Therapeutics plc (MUN:473A)
Germany · Delayed Price · Currency is EUR 0.0160
0.00 (0.00%)
Last updated: Jun 22, 2026, 8:00 AM CET
Adaptimmune Therapeutics Company Description
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom.
The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics plc
| Country | United Kingdom |
| Founded | 2008 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 506 |
| CEO | Christopher Hill |
Contact Details
Address: The Innovation Centre Abingdon, OX14 4RY United Kingdom | |
| Phone | 44 12 3543 0000 |
| Website | adaptimmune.com |
Stock Details
| Ticker Symbol | 473A |
| Exchange | Munich Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher Hill | Chief Executive Officer |
| Christopher Hill | Chief Financial Officer |
| Juli Miller | Head of Investor Relations |